Biotech and Pharmaceuticals Pharmaceuticals

More

  • GSK & Pharma's Foray Into The Blogosphere Friday, 22 May 2009 | 10:39 AM ET
    GlaxoSmithKline

    I've got new competition. Sort of. GlaxoSmithKline sent me an email this morning calling my attention to its new external blog, "American Health: More Than Medicine." A pretty long name for a blog, one that screams that it went through the corporate approval wringer, but at least GSK is putting itself out there.

  • Amylin & Biogen Idec Activists, ASCO & ADA Thursday, 21 May 2009 | 12:49 PM ET
    Amylin

    It's going to be a crazy busy, stressful couple of weeks. A shareholder meeting, a medical meeting, then another shareholder meeting and finally another medical meeting.

  • Bayer And I Go To Pot Thursday, 21 May 2009 | 10:29 AM ET
    GW Pharmaceuticals

    I didn’t inhale. It’s the truth. I swear. I have never ever taken a toke on a joint or even a cigarette. Growing up, my parents were both smokers and I think I developed such a distaste for the constant cloud that it just never held any appeal for me.

  • Medtronic's Public Relations Devices Tuesday, 19 May 2009 | 1:21 PM ET
    Medtronic

    Medtronic may have set a record. The world's biggest medical device maker put out six press releases this morning.

  • The 'Ponies' Are Coming! Time to Buy Stocks Tuesday, 19 May 2009 | 12:58 PM ET
    4 Ponies

    As investors take up navel gazing after snapping a nine-week rally, one strategist offers some words of wisdom: “Focus on the pony.”

  • Lilly's Lechleiter Lights A Fire Thursday, 14 May 2009 | 2:24 PM ET

    Pfizer Chairman and CEO Jeff Kindler last year repeatedly said big deals in big pharma don't work. But, he added, he'd never say never. And sure enough, this year Kindler's buying Wyeth.

  • M Is For Boston Scientific And Pfizer Thursday, 14 May 2009 | 12:23 PM ET
    boston_scientific.jpg

    This takes the prize for the most dangerously optimistic acronym for a clinical trial. But MADIT (pronounced "made it") made it. Some folks with a lot of chutzpah at Guidant, now owned by Boston Scientific, apparently came up with the name for their big studies on implantable cardio defibrillators.

  • Cramer: Prepare for Sector Rotation? Wednesday, 13 May 2009 | 7:49 PM ET

    Wall Street looks ready to transfer funds from bullish to bearish names, the Mad Money host says.

  • The Pfizer "Viagrat" Backstory Wednesday, 13 May 2009 | 1:23 PM ET
    Pfizer

    Over the past few months I've blogged a couple of times about the public service announcement Pfizer produced in the UK to discourage guys from buying and taking counterfeit Viagra.

  • The Novartis Apprentice: You're Hired! Wednesday, 13 May 2009 | 11:16 AM ET
    Novartis Headquarters

    What does it say when a drugmaker hires a Goldman Sachs investment banker as its next Chief Financial Officer? That's the question I'm asking after Novartis announced that it's tapped a managing director of investment banking at Goldman Sachs, Jonathan Symonds, as its CFO apprentice.

  • Carl Icahn Takes On Biogen Idec ... Again Tuesday, 12 May 2009 | 10:23 AM ET
    Carl Icahn

    Billionaire activist investor (It seems it's become almost de rigueur to put those three words before his name) Carl Icahn is apparently so busy waging a proxy fight against biotechs Amylin Pharmaceuticals and Biogen Idec that he hasn't posted a new blog entry in nearly a month.

  • There’s Still Room to Buy Stocks: Barton Biggs Tuesday, 12 May 2009 | 10:00 AM ET

    This is not a bear market rally but a cyclical bull market, said Barton Biggs, managing partner at Traxis Partners. "We’re about half or 60 percent of the way through the upside.”

  • There's No ME in aMYlin Monday, 11 May 2009 | 10:19 AM ET
    Amylin

    Imagine my surprise when I got an email over the weekend from "Diabetic Investor" newsletter editor David Kliff informing me that Amylin Pharmaceuticals is quoting me in a letter to shareholders.

  • Taking A Shot At GlaxoSmithKline Friday, 8 May 2009 | 12:18 PM ET
    GlaxoSmithKline

    The Glaxo announcement contained the results of the first head-to-head study of GSK’s Cervarix versus Merck’s Gardasil. They’re the shots for the sexually transmitted virus that can cause genital warts and cervical cancer. MRK’s is already on the market. GSK’s has been delayed in getting there.

  • Merck Cancer Shot Offers Longer Protection: Study Friday, 8 May 2009 | 6:35 AM ET

    A new study shows that Merck's Gardasil vaccine protects some young women from a strain of a sexually transmitted disease that can lead to cervical cancer for nearly a decade.

  • Vanda Snaps Victory From The Jaws Of Defeat Thursday, 7 May 2009 | 3:50 PM ET

    Out of nowhere late yesterday the FDA approved VNDA's schizophrenia drug with the funky name Fanapt.

  • Cheaper Generic Pills Saved US $734 Billion: Lobbyists Thursday, 7 May 2009 | 5:37 AM ET

    Against the backdrop of President Obama's healthcare reform effort, the main lobbying group for the generic drug industry says the U.S. healthcare system saved nearly three-quarters of a trillion dollars over the past ten years on generic drugs.

  • Roche & Genentech: Get It Together Wednesday, 6 May 2009 | 12:32 PM ET

    It's a new world. Before Roche bought Genentech, stock-moving drug development milestones for DNA were closely followed by the news media, analysts and investors. But because the Swiss drugmaker Roche only trades over-the-counter in the U.S., the information isn't as "actionable" as it used to be when DNA was around.

  • Battlin' Over Amylin Wednesday, 6 May 2009 | 11:07 AM ET
    Amylin

    You gotta love a good proxy fight, especially when you have one of the kings of shareholder activism, Carl Icahn, in the ring. And lately, I've been getting bombarded by emails from representatives of all corners.

  • Keys to a Continued Rally Tuesday, 5 May 2009 | 8:39 PM ET

    Cramer explains why the market stalled today and what we need to go higher.